Versant Capital Management’s Entrada Therapeutics TRDA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$26.7K Sell
4,205
-16
-0.4% -$111 ﹤0.01% 1795
2026
Q2
$31.1K Buy
4,221
+175
+4% +$1.68K ﹤0.01% 1696
2026
Q1
$51.1K Hold
4,046
– – 0.01% 1231
2025
Q4
$41.6K Buy
4,046
+27
+0.7% +$228 0.01% 1187
2025
Q3
$23.3K Buy
4,019
+2,555
+175% +$14.9K ﹤0.01% 1502
2025
Q2
$9.8K Buy
+1,464
New +$11.8K ﹤0.01% 1898

Other funds holding TRDA

Versant Capital Management's TRDA Position: Q3 2026 in Review

Versant Capital Management reduced its Entrada Therapeutics (TRDA) stake by 0.38% in Q3 2026, selling an estimated $111 and leaving 4,205 shares worth $26.7K. The position accounts for ﹤0.01% of the portfolio, ranked #1795.

Versant Capital Management first reported a position in TRDA in Q2 2025 and has held it in 6 quarters since. The position peaked at $51.1K in Q1 2026. 129 funds tracked by Wall St. Rank hold TRDA as of Q3 2026.

  • Versant Capital Management held 4,205 shares of Entrada Therapeutics worth $26.7K as of Q3 2026.
  • Versant Capital Management sold 16 Entrada Therapeutics shares in Q3 2026, an estimated $111.
  • Entrada Therapeutics made up ﹤0.01% of Versant Capital Management's portfolio in Q3 2026, its #1795 holding.
  • Versant Capital Management first reported a position in Entrada Therapeutics in Q2 2025 and has held it in 6 quarters since.
  • Versant Capital Management's Entrada Therapeutics position peaked at $51.1K in Q1 2026.
  • 129 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q3 2026.

Based on Versant Capital Management's 13F filing for Q3 2026, filed 2 Oct 2026.